ABC Safe Drug Act
Summary
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The ABC Safe Drug Act remains in the Senate Finance Committee with no action since its April 2025 introduction.
- 2.The bill phases in China API restrictions for federal drug purchases through 2030, but actual funding depends on HHS waivers and tax expenditures.
- 3.No market impact is currently reflected in pharma stock prices; recent negative 7-day changes are attributable to broader sector factors, not this bill.
Market Implications
The ABC Safe Drug Act presents a long-term structural tailwind for U.S.-based API and finished dosage form manufacturers, but the current legislative stage (referred to committee, no hearings) means zero near-term market impact. Investors should not trade based on this bill. The five major pharma stocks tracked ($PFE $26.48, $MRK $110.03, $227.79, $LLY $874.00, $AMGN $339.57) show negative 7-day momentum for four of five, consistent with general pharma sector weakness from IRA pricing negotiations and pipeline issues. The bill's tax incentive provision is a modest positive for companies already planning domestic manufacturing capex, but it is temporary (2024-2030) and does not justify premium valuations on its own.
Full Analysis
-
What happened and its current status: On April 10, 2025, Senator Tom Cotton (R-AR) introduced S. 1407, the ABC Safe Drug Act. The bill was read twice and referred to the Senate Committee on Finance, where it remains as of the analysis date (April 28, 2026). It is an early-stage bill with no further legislative action. The bill would restrict federal health programs (HHS, VA, DoD, etc.) from purchasing drugs that contain active pharmaceutical ingredients (APIs) manufactured in China. It phases in: by January 2028, at least 60% of APIs must be from non-China approved countries; by January 2030, 100%. HHS can grant waivers through 2030, but none beyond that. The bill also includes labeling requirements (country of origin for each active ingredient) and a temporary 100% bonus depreciation (expensing) for qualified pharmaceutical and medical device manufacturing property placed in service after December 31, 2024 and before January 1, 2031.
-
The money trail — authorization vs. appropriation: This bill authorizes no direct federal spending. The restriction reduces federal procurement options, potentially increasing drug costs if domestic alternatives are more expensive. The tax incentive is a revenue provision: it allows companies to immediately deduct 100% of qualified manufacturing property costs, reducing federal tax revenue. The bill does not appropriate funds for reshoring or facility construction. The actual fiscal impact depends on IRS tax expenditure estimates and HHS waiver decisions.
-
Structural winners and losers: Winners: U.S. contract manufacturers and suppliers of pharmaceutical APIs and intermediates that do not source from China. Pure-play API manufacturers like $CAMT (Cambrex) or $CDMO (Avid Bioservices, now part of $CXM?) would benefit from increased demand for domestic API production. Companies with established U.S. biologics manufacturing ($AMGN, ) are less exposed to China API reliance. Losers: Big pharma with significant China-sourced APIs for small-molecule drugs face compliance costs. The tax incentive partially offsets these costs. Diversification timelines matter: companies needing to build new U.S. facilities will take years, and the tax incentive window closes in 2030.
-
Real market data: The provided Yahoo Finance data shows the five major pharma tickers in a broad 7-day decline: $PFE -1.19%, $MRK -2.53%, +0.75% (outlier), $LLY -5.15%, $AMGN -1.84%. The 30-day changes range from -0.48% ($LLY) to -8.02% ($MRK). These movements are consistent with sector-wide headwinds (e.g., IRA drug pricing negotiation, pipeline setbacks) rather than the ABC Safe Drug Act, which is at a procedural early stage with zero market pricing of its impact.
-
Timeline: The bill has no scheduled markup or hearing. It sits in the Senate Finance Committee. For it to become law, it must pass the committee, then the full Senate, then the House (or be inserted into must-pass legislation), and be signed by the President. The 119th Congress runs through January 2027, giving roughly 8 months for legislative action. The current bill's enforcement dates (2028/2030) are beyond the 119th Congress, meaning even if passed, implementation is years away. The recent Presidential Executive Order on Accelerating Medical Treatments for Serious Mental Illness (April 18, 2026) is unrelated to this bill's supply chain focus.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Phase-in restriction on federal health programs purchasing drugs containing active pharmaceutical ingredients (APIs) manufactured in China, starting 2028 with a 60% non-China threshold, reaching 100% by 2030. Temporary 100% bonus depreciation for domestic pharmaceutical and medical device manufacturing property placed in service before 2031.
Who must act
Pfizer Inc., as a major supplier of drugs to U.S. federal health programs (Medicare, Medicaid, VA, DoD), must source or manufacture APIs outside China by the 2028/2030 deadlines.
What happens
Pfizer faces supply chain restructuring costs for qualifying active ingredients to avoid losing federal program revenue, but gains a tax incentive (100% expensing) for domestic manufacturing investments placed in service by 2030.
Stock impact
Pfizer derives significant revenue from U.S. federal programs. The mandate increases near-term capital expenditure for domestic API production or alternate sourcing; the tax incentive partially offsets costs. Current market data shows PFE at $26.48, near the lower end of its 52-week range ($21.97–$28.75), with a 7-day decline of -1.19% and 30-day decline of -2.07%, reflecting broader sector weakness rather than specific bill impact.
What the bill does
Same as above: federal procurement restriction on China-sourced APIs and temporary tax incentive for domestic manufacturing property.
Who must act
Merck & Co., Inc., supplier to federal health programs, must ensure its drug supply chain for APIs sourced from China meets the 2028/2030 thresholds.
What happens
Merck incurs compliance costs for API sourcing changes or reshoring, but benefits from 100% bonus depreciation on qualifying U.S. manufacturing equipment placed in service through 2030.
Stock impact
Merck's product portfolio includes key drugs supplied to federal programs. The bill's early-stage status (referred to committee) limits immediate operational pressure. MRK at $110.03 is off its 52-week high of $125.14, with a notable 7-day decline of -2.53% and 30-day decline of -8.02%, suggesting broader market or company-specific headwinds beyond this bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
Protecting Americans from Unsafe Drugs Act of 2026
American Innovation and R&D Competitiveness Act of 2025
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Most Favored Patient Act of 2026
Skinny Labels, Big Savings Act
Lowering Drug Costs for American Families Act
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Declaration of Emergency and Authorization for Temporary Duty Free Importation of Phosphate Fertilizer Morocco
This proclamation declares an emergency under the Tariff Act due to insufficient domestic phosphate fertilizer supply, and authorizes duty-free importation of phosphate fertilizer from Morocco for up to 8 months. It directs the Secretaries of Treasury and Commerce to permit these imports without duties or anti-dumping fees, and monitor the situation.
Lowering the Cost of Living by Promoting the Freedom to Fix
This memorandum directs the EPA Administrator to issue guidance within 30 days clarifying that consumers can perform emission repairs without violating the Clean Air Act, encourages the EPA to approve alternative aftermarket parts certification processes beyond CARB, and deprioritizes enforcement against individuals who in good faith repair their own vehicles to original configuration.
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →